[Ischaemic cardiogenic shock. Where do we stand in 2012?].
With a stable frequency (about 5% of acute coronary syndromes) and a mortality of nearly 45%, cardiogenic shock (CS), especially when it occurs in the immediate waning of myocardial infarction, still represents a therapeutic challenge. In this review, will be detailed the actual epidemiologic data of CS, its physiopathology and the different modalities of treatments available to the interventional cardiologist, especially the coronary revascularisation and the percutaneous left ventricular assistance, whether by intra-aortic balloon counterpulsation or by more complex systems.
Service de cardiologie et maladies vasculaires, CHU de Rennes, 35000 Rennes, France. guillaume.leurent@chu-rennes.fr
G
G
Leurent
D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D019317:Evidence-Based Medicine; D005602:France / Q000453:epidemiology; D006801:Humans; D007423:Intra-Aortic Balloon Pumping / Q000379:methods; D009203:Myocardial Infarction / Q000150:complications* / Q000628:therapy; D017410:Practice Guidelines as Topic; D012770:Shock, Cardiogenic / Q000453:epidemiology* / Q000209:etiology / Q000401:mortality / Q000503:physiopathology / Q000601:surgery* / Q000628:therapy; D015996:Survival Rate; D016896:Treatment Outcome